Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Официальное название

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)

Обзор

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.

Подробное описание

This is a randomized, placebo-controlled, double-blind, multi-center, multi-national, phase III trial, to assess the efficacy and safety of trimodulin compared to placebo treatment, as adjunctive treatment to SoC in hospitalized subjects with sCAP receiving IMV.

Subjects will be randomized on a 1:1 basis to receive trimodulin or placebo, stratified by center. Investigational medicinal product (IMP) treatments will be blinded.

Subject will be administered IMP once daily on 5 consecutive days (day 1 through day 5) adjunctive to SoC. The subsequent follow-up phase comprises maximally 23 days (day 6 through day 28) followed by an end-of-follow-up visit/telephone call on day 29 \[+3\]. For subjects still in the hospital (trial site) after day 29, an extended follow-up is conducted until discharge or until day 90. For all subjects alive on day 29, a closing visit/telephone call on day 91 \[+10\] will be done.

Вмешательства

• Препарат Trimodulin
  IMP will be administered via IV infusion on 5 consecutive days
• Препарат Placebo (human albumin 1%)
  IMP will be administered via IV infusion on 5 consecutive days

Первичные конечные точки

• 28-day all-cause mortality rate [Срок оценки: Between days 1-29]

Вторичные конечные точки (12)

• 90-day all-cause mortality rate [Срок оценки: Between days 1-91]
• Deterioration rate (up to day 29) [Срок оценки: Up to day 29]
• Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 7 [Срок оценки: Between baseline and Day 7]
• Proportion of subjects with clinical cure of pneumonia up to day 29 [Срок оценки: Up to day 29]
• Days of invasive mechanical ventilation (IMV) up to day 29 [Срок оценки: Up to day 29]
• Ventilator-free days (VFD) until day 29 [Срок оценки: Until day 29]
• Days with oxygen supply up to day 29 [Срок оценки: Up to day 29]
• Proportion of subjects with oxygen supply on days 7, 14, 21 and 29 [Срок оценки: On days 7, 14, 21 and 29]
• Days in intensive care unit (ICU) up to day 29 [Срок оценки: Up to day 29]
• Time to discharge from ICU [Срок оценки: Until day 91]
• Proportion of subjects in ICU on days 7, 14, 21 and 29 [Срок оценки: On days 7, 14, 21, 29]
• Days of hospitalization up to day 29 [Срок оценки: Up to day 29]

Критерии участия

Main Inclusion Criteria:

• Written informed consent.
• Hospitalized, adult (≥ 18 years of age) subject; In US only: ≥ 12 years of age
• Signs of inflammation based on C-reactive protein threshold level.
• Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission.
• Radiological (or other imaging technology) evidence consistent with active pneumonia.
• Acute respiratory failure requiring IMV.

Main Exclusion Criteria:

• For an incapacitated subject: any indication that the subject's presumed will would be against inclusion in the trial.
• Pregnant or lactating women.
• Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment.
• Subjects on ECMO at start of IMP treatment.
• Suspected hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).
• Subjects discharged from hospital within the previous 14 days.
• Defined neutrophil counts up to one calendar day prior to start of IMP treatment.
• Defined platelet counts up to one calendar day prior to start of IMP treatment.
• Defined hemoglobin within up to one calendar day prior to start of IMP treatment.
• Pre-existing hemolytic disease.
• Thromboembolic events (TEEs) caused by other reasons than the current sCAP within 3 months before start of IMP treatment unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment.
• Severe renal impairment prior to start of IMP treatment.
• End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS).
• Pre-existing severe lung diseases concomitant to current sCAP (e.g. active tuberculosis, active lung cancer).
• Pre-existing decompensated heart failure.
• Pre-existing severe hepatic cirrhosis (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma.
• Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin / placebo.
• Selective immunoglobulin A (IgA) deficiency with known antibodies to IgA.
• Life expectancy of less than 90 days, according to the investigator's clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions.
• Morbid obesity with high body mass index (BMI) ≥ 40 kg/m2, or malnutrition with low BMI < 16 kg/m2.
• Treatment with polyvalent immunoglobulin preparations during the last 21 days before start of IMP treatment.
• Known treatment with predefined medications, during the last 2 days before start of IMP treatment.
• Hematopoietic stem cell transplantation or previous lung transplantation.
• Treatment with investigational medications/procedures not according to SoC of the trial site, due to participation in another interventional clinical trial within 30 days before start of IMP treatment, or previous treatment with IMP in this clinical trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Франция · 20 центров

• Centre Hospitalier Victor Dupouy — Argenteuil
• Hôpital Louis Mourier — Colombes
• CHU de Grenoble - Hôpital Albert Michallon — Grenoble
• CHRU Lille - Hôpital Salengro — Lille
• CHU de Limoges - Hôpital Dupuytren — Limoges
• Centre Hospitalier de Melun — Melun
• CHU Nice-Hopital de l' Archet — Nice
• CHU Nice Hopital Pasteur 2 — Nice
• … и ещё 12 центров

США · 19 центров

• Pulmonary Associates of Mobile, P.C. — Mobile
• University of California San Francisco-Fresno — Fresno
• UC Davis Health — Sacramento
• Augusta University — Augusta
• Sparrow Clinical Research Institute — Lansing
• William Beaumont Hospital — Royal Oak
• University of Missouri Clinical Research Center — Columbia
• Hannibal Clinic — Hannibal
• … и ещё 11 центров

Испания · 16 центров

Список центров уточняется — проверьте первичный протокол.

Аргентина · 15 центров

• Sanatorio Parque S.A. Privado — San Vicente
• Sanatorio Parque S.A — Rosario
• Sanatorio Guemes — Buenos Aires
• Hospital General de Agudos Dr. J. M. Ramos Mejia — Buenos Aires
• CEMIC — Ciudad Autonoma de Buenos Aire
• Sanatorio de la Trinidad Mitre — Ciudad Autonoma de Buenos Aire
• Hospital Italiano de Buenos Aires — Ciudad Autonoma de Buenos Aire
• Hospital General de Agudos Dr. Ignacio Pirovano — Ciudad Autonoma de Buenos Aire
• … и ещё 7 центров

Бельгия · 12 центров

• Onze Lieve Vrouw Ziekenhuis — Aalst
• AZ Sint-Jan — Bruges
• Hopital Erasme — Brussels
• Cliniques Universitaires Saint-Luc — Brussels
• Antwerp University Hospital (UZA) — Edegem
• ZOL — Genk
• AZ Maria Middelares — Ghent
• Universitair Ziekenhuis Brussel — Jette
• … и ещё 4 центра

Бразилия · 12 центров

• UPECLIN - Unidade de Pesquisa Clínica — Botucatu
• HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas — Campinas
• Hospital do Rocio — Campo Largo
• Universidade de Caxias do Sul, IPCEM - Instituto de Pesquisa Clínica para Estudos Multicên — Caxias do Sul
• Hospital de Clínicas de Passo Fundo — Passo Fundo
• Irmandade da Santa Casa de Misericórdia de Porto Alegre — Porto Alegre
• Hospital de Clínicas de Porto Alegre — Porto Alegre
• Hospital Ernesto Dornelles — Porto Alegre
• … и ещё 4 центра

Израиль · 8 центров

Список центров уточняется — проверьте первичный протокол.

Филиппины · 8 центров

Список центров уточняется — проверьте первичный протокол.

ЮАР · 7 центров

Список центров уточняется — проверьте первичный протокол.

Австралия · 6 центров

• Princess Alexandra Hospital — Woolloongabba
• Monash Medical Centre — Clayton
• Sir Charles Gairdner Hospital — Nedlands
• Footscray Hospital — Footscray
• Austin Health — Heidelberg
• Sunshine Hospital — Saint Albans

Венгрия · 6 центров

Список центров уточняется — проверьте первичный протокол.

Германия · 5 центров

Список центров уточняется — проверьте первичный протокол.

Великобритания · 5 центров

Список центров уточняется — проверьте первичный протокол.

Чехия · 4 центра

• Fakultni nemocnice u sv. Anny v Brne — Brno
• Oblastni nemocnice Kolin a.s. — Kolín
• Hospital Kyjov — Kyjov
• Fakultni nemocnice Kralovske Vinohrady — Prague

Ирландия · 4 центра

Список центров уточняется — проверьте первичный протокол.

Румыния · 3 центра

Список центров уточняется — проверьте первичный протокол.

Австрия · 2 центра

• KABEG-Klinikum Klagenfurt — Klagenfurt
• AKH - Medizinische Universität Wien — Vienna

Новая Зеландия · 2 центра

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT05722938 · 996

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗